Halaven

HALAVEN Side Effects by Likelihood and Severity

low amount of calcium in the blood low amount of potassium in the blood a significant drop in a certain type of white blood cell called a neutrophil ... read more

Does HALAVEN Interact with other Medications?

These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Sorry, we have no data ... read more

Cancer-fighting sponges

Halaven, a drug derived from a sea sponge compound came on the market in Nov. 2010, and has improved survival among women who have metastatic breast cancer. NBC’s Anne Thompson reports. read more

FDA Approves Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer

Patients administered chemotherapy received capecitabine (Xeloda; 20.1%), eribulin (Halaven; 51.1%), gemcitabine (10.3%), paclitaxel (8.2%), or nab-paclitaxel (Abraxane; 10.3%). Of those enrolled in ... read more

Knight Therapeutics Reports Second Quarter 2022 Results

Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, ... read more

FY2022 EPS Estimates for Knight Therapeutics Inc. Lowered by National Bank Financial (TSE:GUD)

National Bank Financial lowered their FY2022 earnings estimates for Knight Therapeutics in a report issued on Monday, August 8th. National Bank Financial analyst E. Leno now forecasts that the company ... read more

Stocks in play: Knight Therapeutics Inc

Announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven® (eribulin) injection. Halaven® (eribulin) injection is indicated for the treatment ... read more

Connective Tissue Oncology Society

PFS rate of 69% at 12 weeks in liposarcoma patients with eribulin and pembrolizumab A combination of eribulin (Halaven) and pembrolizumab (Keytruda) offered promising results in patients with ... read more

Eisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call Transcript

Q1 2023 Earnings Conference Call August 5, 2022 3:00 AM ET Company Participants Tatsuyuki Yasuno - SVP, CFO & Chief IR Officer Ivan Cheung - SVP, ... read more

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021

HALAVEN, a halichondrin class microtubule dynamics inhibitor, "eribulin"). At this congress, differences in outcomes by histology and prior therapy in the pivotal Phase 3 Study 309/KEYNOTE-775 ... read more